Overview of Dr. Lito
Dr. Piro Lito is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Michigan State University College of Human Medicine and has been in practice 9 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 40 publications and over 500 citings.
Office
1275 York Avenue
New York, NY 10065
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2014
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2008 - 2010
Michigan State University College of Human MedicineClass of 2008
Certifications & Licensure
NY State Medical License 2010 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Seldin Smith Award for Pioneering Research The American Society for Clinical Investigation, 2022
- Pershing Square Sohn Prize Pershing Square Sohn Cancer Research Alliance, 2022
- Life Sciences Breakthroughs of the Year Falling Walls Foundation, 2022
- Join now to see all
Publications & Presentations
PubMed
- Preclinical Evaluation of [I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors.Raik Artschwager, Teja M Kalidindi, Delissa Johnson, Christopher Brennan, Zachary V Samuels
ACS Pharmacology & Translational Science. 2024-12-13 - 1 citationsRAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.Junya Sango, Saul Carcamo, Maria Sirenko, Abhishek Maiti, Hager Mansour
Nature. 2024-12-01 - 1 citationsPharmacological restoration of GTP hydrolysis by mutant RAS.Antonio Cuevas-Navarro, Yasin Pourfarjam, Feng Hu, Diego J Rodriguez, Alberto Vides
Nature. 2024-10-30
Press Mentions
MSK Research Highlights, November 6, 2024November 6th, 2024- Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory BoardFebruary 8th, 2022
- Mission Bio's Tapestri Platform Helps Elucidate Resistance Mechanisms to Lung Cancer Drugs in Nature PublicationNovember 23rd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
